Overview

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

Status:
NOT_YET_RECRUITING
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a better job of killing cancer before surgery compared to chemotherapy alone.
Phase:
PHASE2
Details
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborator:
Replimune Inc.
Treatments:
Docetaxel
Filgrastim
Fluorouracil
Leucovorin
Oxaliplatin
pegfilgrastim